Related Experiment Videos
Homoharringtonine: history, current research, and future direction
H M Kantarjian1, M Talpaz, V Santini
1Department of Leukemia, M. D. Anderson Cancer Center, Houston, Texas 77030, USA. hkantarj@mdanderson.org
Cancer
|December 18, 2001
Summary
Homoharringtonine (HHT) shows promise in treating hematologic malignancies, particularly leukemia. Further research is needed to optimize its use and explore new derivatives for improved efficacy and reduced toxicity.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Cephalotoxine esters, including homoharringtonine (HHT), have demonstrated preliminary efficacy in leukemia treatment.
- Initial studies in China and the U.S. indicated encouraging activity of HHT in hematologic cancers.
Purpose of the Study:
- To review existing literature on homoharringtonine (HHT).
- To examine preclinical studies and Phase I-II trials of HHT in hematologic malignancies and solid tumors.
Main Methods:
- Literature review of preclinical and clinical studies.
- Analysis of Phase I-II trials investigating HHT in various cancers.
Main Results:
- HHT and analogues induce cancer cell differentiation and apoptosis.
- Positive results observed in acute myeloid leukemia, myelodysplastic syndrome, acute promyelocytic leukemia, and chronic myeloid leukemia (CML).
- Negative results in solid tumors; cardiovascular complications noted with short infusions, reduced with continuous schedules.
Conclusions:
- Homoharringtonine (HHT) and its derivatives exhibit promising activity in hematologic malignancies.
- Further investigation is warranted to optimize HHT therapy and develop novel derivatives.